These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 26155290)

  • 1. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
    Mattes MD; Bhatia JK; Metzger D; Ashamalla H; Katsoulakis E
    J Breast Cancer; 2015 Jun; 18(2):143-8. PubMed ID: 26155290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis: A Retrospective Cohort Study.
    He ZY; Wu SG; Yang Q; Sun JY; Li FY; Lin Q; Lin HX
    Medicine (Baltimore); 2015 Dec; 94(48):e2213. PubMed ID: 26632910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients.
    Gallagher J; Elleson KM; Englander K; Chintapally N; Sun W; Whiting J; Laronga C; Lee MC
    J Surg Res; 2024 Mar; 295():327-331. PubMed ID: 38061237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
    Senel F
    Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
    Parise CA; Caggiano V
    Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
    Crabb SJ; Cheang MC; Leung S; Immonen T; Nielsen TO; Huntsman DD; Bajdik CD; Chia SK
    Clin Breast Cancer; 2008 Jun; 8(3):249-56. PubMed ID: 18650155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Boughey JC
    Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
    Vane MLG; van Nijnatten TJA; Nelemans PJ; Lobbes MBI; van Roozendaal LM; Kooreman LFS; Keymeulen KBMI; Smidt ML; Schipper RJ
    Eur J Surg Oncol; 2019 Apr; 45(4):573-577. PubMed ID: 30732971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of risk factors of axillary lymph node metastasis and prognosis in T1 breast cancer: a large-scale retrospective study based on the SEER database].
    Wang WY; Meng XZ; Li N; Zeng HM; Liu JX; Feng KX; Wang PL; Wang X
    Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2152-2158. PubMed ID: 34275251
    [No Abstract]   [Full Text] [Related]  

  • 15. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
    Ahmed AR
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
    Fan Y; Wang Y; He L; Imani S; Wen Q
    ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of nodal metastases in early stage HER2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery.
    Faleh S; Prakash I; Eisenberg E; Basik M; Boileau JF; Tejera D; Panet F; Buhlaiga N; Meterissian S; Wong SM
    Eur J Surg Oncol; 2023 Aug; 49(8):1411-1416. PubMed ID: 37031045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
    Ba JL; Liu CG; Jin F
    Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.